Welcome to our dedicated page for Lexicon Pharmaceuticals SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexicon Pharmaceuticals, Inc. filings document a biopharmaceutical issuer with common stock listed on The Nasdaq Capital Market under LXRX. Its regulatory record includes Form 8-K reports on operating and financial results, clinical and regulatory updates, material agreements, debt financing, equity offerings and conversions of preferred stock into common stock.
Proxy and governance filings describe director elections, executive compensation, equity incentive plans and shareholder voting matters. Registration and prospectus-related disclosures address common-stock issuance programs, capital structure and public-market financing alongside the company's development programs in cardiometabolic and neurologic disease areas.
LEXICON PHARMACEUTICALS director Diane E. Sullivan received new equity awards as part of her compensation. On May 1, 2026, she was granted stock options covering 43,478 shares of common stock at an exercise price of $1.61 per share, expiring on May 1, 2036. The option vests in three equal annual installments on each of the first three anniversaries of the grant date.
She was also granted 35,714 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock. The RSUs vest in full on the first anniversary of the grant date. These are non-cash, compensation-related grants, with no open-market purchases or sales reported in this filing.
Lexicon Pharmaceuticals director Raymond Debbane received new equity awards. On May 1, he was granted stock options for 43,478 shares of common stock at an exercise price of $1.61 per share, expiring in 2036.
The option vests in three equal annual installments on each of the first three anniversaries of the grant date. He also received 35,714 restricted stock units, which vest in full on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock.
Lexicon Pharmaceuticals, Inc. converted its Series B Convertible Preferred Stock into common shares and expanded its equity plans and authorized share capital. On April 30, 2026, all 408,434.7 outstanding Series B preferred shares were automatically converted into 20,421,735 shares of common stock at a 50-to-1 ratio under the existing terms, relying on a Section 3(a)(9) exemption.
Stockholders approved a 2026 Equity Incentive Plan, increasing the common stock available for awards from 75,000,000 to 90,000,000 shares, and a 2026 Non-Employee Directors’ Equity Incentive Plan, increasing its pool from 4,000,000 to 6,000,000 shares. Both plans now run through February 12, 2036. Lexicon also filed a Seventh Amended and Restated Certificate of Incorporation, effective on filing, raising authorized common stock from 450,000,000 to 900,000,000 shares, with related charter and equity plan items and auditor ratification approved at the annual meeting.
Lexicon Pharmaceuticals filed its annual report on Form 10-K for the fiscal year ended December 31, 2025. The company reported an aggregate market value of voting stock held by non-affiliates of $170.0 million based on a $0.95 closing price as of June 30, 2025, and stated 423,680,611 shares outstanding as of March 4, 2026.
The company is focused on advancing sotagliflozin (commercialized as INPEFA and pursued as ZYNQUISTA), pilavapadin (LX9211), and LX9851. FDA proceedings for ZYNQUISTA include two complete response letters and an ongoing public Notice of Opportunity for Hearing; the company may resubmit its NDA contingent on third-party study data. Lexicon disclosed collaboration agreements with Novo Nordisk, Viatris and Bristol-Myers Squibb and reported $61.1 million in R&D expenses for 2025.
Lexicon Pharmaceuticals is asking stockholders to vote at its April 30, 2026 annual meeting on several key items. The company proposes doubling authorized common shares from 450,000,000 to 900,000,000, which would leave 376,875,534 shares authorized but not issued or reserved after assumed conversions and plan approvals. Stockholders are also asked to approve a new 2026 Equity Incentive Plan increasing the share pool to 90,000,000 and a 2026 Non-Employee Directors’ Equity Incentive Plan with up to 6,000,000 shares. Other proposals include electing three Class II directors, an advisory vote on executive compensation, and ratifying Ernst & Young LLP as independent auditors for the year ending December 31, 2026. Common stockholders of record on March 6, 2026, when 423,680,611 shares were outstanding, are entitled to one vote per share.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on small‑molecule drugs for cardiovascular, metabolic and neuropathic diseases, built on internal target discovery from about 5,000 genes. The company devotes most resources to sotagliflozin, pilavapadin, LX9851 and commercialization of INPEFA.
INPEFA (sotagliflozin) is approved in the U.S. to reduce cardiovascular death and heart‑failure events in adults with heart failure or type 2 diabetes, chronic kidney disease and other cardiovascular risk factors, and is sold mainly through major wholesalers and a mail‑order pharmacy. Sotagliflozin is also in the SONATA‑HCM Phase 3 trial for hypertrophic cardiomyopathy and is being pursued as ZYNQUISTA for type 1 diabetes after FDA complete response letters, with a potential NDA resubmission supported by the STENO1 study.
Pilavapadin has shown evidence of effect in multiple Phase 2 neuropathic pain trials and holds FDA Fast Track designation for diabetic peripheral neuropathic pain, with Phase 3 advancement contingent on third‑party collaboration. LX9851 for obesity is licensed exclusively to Novo Nordisk, which paid a $45 million upfront and a $10 million milestone and may owe up to $950 million in additional milestones plus tiered royalties. Sotagliflozin rights in certain territories are licensed to Viatris, which paid a $25 million upfront and may pay up to $197 million in milestones plus royalties.
Lexicon Pharmaceuticals reported 2025 results showing higher revenue and a sharply reduced loss while advancing its pipeline. Total revenues were $49.8 million in 2025 versus $31.1 million in 2024, largely driven by $45 million of licensing revenue from a Novo Nordisk agreement and $4.6 million of INPEFA net sales.
Net loss narrowed to $50.3 million, or $0.14 per share, from $200.4 million, or $0.63 per share, helped by major cost reductions. Research and development expenses fell to $61.1 million from $84.5 million, and selling, general and administrative expenses dropped to $37.3 million from $143.1 million, reflecting a strategic repositioning and reduced INPEFA marketing.
As of December 31, 2025, cash, investments and restricted cash totaled $125.2 million, and in February 2026 the company added approximately $96.7 million of net equity proceeds plus a $10 million milestone payment from Novo Nordisk. Key programs progressed, including SONATA-HCM Phase 3 enrollment surpassing 50%, planned 2026 NDA resubmission for ZYNQUISTA in type 1 diabetes, and Phase 3 readiness for pilavapadin in diabetic neuropathic pain.
Lexicon Pharmaceuticals senior vice president Wendy McDermott reported multiple equity award transactions involving restricted stock units and common stock. On February 28, 2026, she exercised or converted several blocks of restricted stock units into common shares at a stated price of $0.00 per share, including a tranche of 144,393 restricted stock units that became common stock. Each restricted stock unit represents the right to receive one share of common stock, and the units vest in three equal annual installments each February 28 following the grant year.
On the same date, 68,107 common shares were withheld at $1.47 per share to satisfy tax withholding obligations, a non‑market transaction classified as a tax‑withholding disposition. After these transactions, McDermott continued to hold common stock directly, reflecting equity compensation rather than open‑market trading.
LEXICON PHARMACEUTICALS, INC. senior vice president Rachel Yap Martens reported equity compensation activity involving restricted stock units and common shares. On February 28, 2026, she exercised 67,090 restricted stock units, converting them into 67,090 shares of common stock at a price of $0.00 per share.
In a related tax event on the same date, 35,826 common shares were disposed of at $1.47 per share to satisfy tax withholding obligations, as described in the footnotes. After these transactions, she held 31,264 shares of common stock and 134,180 restricted stock units directly. Each restricted stock unit represents the right to receive one share of common stock and vests in three equal annual installments each February 28 following the grant year.
LEXICON PHARMACEUTICALS, INC. Senior Vice President and Chief Medical Officer Craig B. Granowitz reported multiple equity award transactions involving restricted stock units and common stock on February 28, 2026.
He exercised or converted restricted stock units into common shares in three separate transactions of 35,790, 74,226, and 202,260 restricted stock units, each at a stated price of $0.00 per unit. Each restricted stock unit represents a contingent right to receive one share of common stock, and these units vest in three equal annual installments on February 28 of each of the three years following the year of grant.
Corresponding non-derivative entries show acquisitions of common stock in matching amounts of 35,790, 74,226, and 202,260 shares, reflecting the settlement of those restricted stock units. A separate transaction disposed of 109,098 shares of common stock at $1.47 per share through withholding of a portion of the issued shares by the company to satisfy the reporting person’s tax withholding obligations. After these transactions, the reporting person directly owned 323,430 shares of common stock.